Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883072 | 0.93 | FFAR1 (0.47) | PARP10FFAR1 | |
| SCHEMBL3882358 | 0.90 | MMP2 (0.45) | FFAR1 | |
| SCHEMBL3880883 | 0.80 | MMP13 (0.47) | PARP10FFAR1 | |
| SCHEMBL3884532 | 0.78 | ADAM17 (0.64) | — | |
| SCHEMBL3887844 | 0.78 | ADAM17 (0.46) | PARP10FFAR1 | |
| SCHEMBL3880168 | 0.76 | PARP10 (0.41) | PARP10FFAR1 | |
| SCHEMBL3880172 | 0.76 | PARP10 (0.41) | PARP10FFAR1 | |
| SCHEMBL3880178 | 0.76 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL3884156 | 0.75 | MMP2 (0.68) | — | |
| SCHEMBL3889770 | 0.74 | MMP2 (0.44) | PARP10FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | PARP10 2037/4885FFAR1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.